11 Results

People

  1. Palomba
    Palomba
  2. Batlevi
    Batlevi
  3. Sauter
    Sauter
  4. Younes
    Younes
  5. Brentjens
    Brentjens
  6. Caron
    Caron
  7. Halton
    Halton
  8. Hamlin
    Hamlin
  9. Horwitz
    Horwitz
  10. Intlekofer
    Intlekofer

Groups

  1. Center for Hematologic Malignancies (11)
  2. Department of Medicine (11)
  3. GSK Faculty (11)
  4. Hematologic Malignancies Research (11)
  5. Hematologic Malignancies, Division of (11)
  6. Lymphoma (11)
  7. Solid Tumor Oncology Division (11)
  8. Bone Marrow Transplant (9)
  9. Executive Committee, Center for Hematologic Malignancies (9)
  10. Nursing (8)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Maria Palomba"
  4. "Solid Tumor Oncology Division"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (1)
Groups
  1. Center for Hematologic Malignancies (11)
  2. Department of Medicine (11)
  3. GSK Faculty (11)
  4. Hematologic Malignancies Research (11)
  5. Hematologic Malignancies, Division of (11)
  6. Lymphoma (11)

More Groups

People
  1. Maria Palomba (11)
  2. Anas Younes (7)
  3. Connie Batlevi (7)
  4. Craig Sauter (7)
  5. Alison Moskowitz (5)
  6. Andrew Intlekofer (5)

More People

Years
  1. 2023 (1)
  2. 2019 (3)
  3. 2018 (2)
  4. 2017 (2)
  5. 2016 (2)
  6. 2005 (1)
Publications
  1. Blood (5)
  2. Biology of Blood and Marrow Transplantation (2)
  3. Hematological Oncology (2)
  4. Clinical Cancer Research (1)
  5. Value in Health (1)
Publishers
  1. American Society of Hematology (5)
  2. Elsevier Inc. (2)
  3. Wiley Blackwell (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy
    Meeting Abstract

    Smith, M.; Littmann, E.; Slingerland, J.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Peled, J. U.; Park, J.; O'Cearbhaill, R.; Mailankody, S.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Intestinal microbiota composition prior to CAR T cell infusion correlates with efficacy and toxicity
    Meeting Abstract

    Smith, M.; Littmann, E. R.; Slingerland, J. B.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Schluter, J.; Park, J. H.; O'Cearbhaill, R.; Mailankody, S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save